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Abstract
Some degree of exertional rhabdomyolysis (ER), striated muscle breakdown associated with strenuous exercise, is a
well-known phenomenon associated with endurance sports. However in rare cases, severe and/or recurrent ER is a
manifestation of an underlying condition, which puts patients at risk for significant morbidity and mortality. Selecting the
patients that need a diagnostic work up of an acute rhabdomyolysis episode is an important task.
Based on the diagnostic work up of three illustrative patients treated in our hospital, retrospectively using the
‘RHABDO’ screening tool, we discuss the clinical and biochemical clues that should trigger further investigation for
an underlying condition. Finally, we describe the most common genetic causes of this clinical syndrome.
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Introduction
Exertional rhabdomyolysis (ER) is a frequent syndrome
treated by a wide variety of medical disciplines.
For these different specialties, it is often difficult to
distinguish a normal physiological response to
exercise—including muscle soreness and an elevated
blood creatine kinase (CK) level—from a pathological
and clinically more relevant response in relation to the
type of exercise. The latter again includesmuscle soreness
(albeit more often of a more severe and/or delayed type),
fever, and biochemical evidence of rhabdomyolysis.
The distinction between both responses is neverthe-
less important as a patient having an underlying genetic
condition is prone to recurrence and should therefore
be warned about the risk. Consequently, clinical and
biochemical findings have to be interpreted adequately,
and clues for further non-invasive and invasive inves-
tigations defined.
A recent review article aimed to define the triggers
for further investigation, and a screening tool under the
acronym ‘RHABDO’ was proposed.1 Even though this
practical tool is available, all too often ER necessitat-
ing hospital admission is not properly investigated for
an underlying cause, even when several clues warrant
this to be the case.
In this article, we review the diagnostic work up in
three illustrative cases treated at our institution by apply-
ing this acronym, and present a summary of the most
common underlying causes of this clinical syndrome.
Written informed consent was obtained from all
participating patients and the study was approved by
the institutional review board.
Case descriptions
The following three patients were treated for severe ER
by a multidisciplinary team of emergency physicians,
intensive care specialists, neurologists, and the
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malignant hyperthermia (MH) laboratory of the
University Hospital of Antwerp in Belgium.
Case 1. Male, 21 years of age. In December 2016, at the
age of 18 years, the patient presented with the com-
plaint of severe cramping pain after having played
soccer, even though he had not experienced the game
as intense. Outside temperature was around 5!C.
At admission to the emergency department, his CK
level exceeded 45,000 IU/L and myoglobinuria was
found. He stayed in the hospital for one week and no
complications occurred. A second episode was noted in
March 2018 during a tournament, again in normal
ambient temperatures, in which he played several
matches on consecutive days. Myalgia was pronounced
but less severe than in 2016; his CK level was 7500 IU/
L. Triggers other than physical effort could not
be identified.
Neurological examination was normal. Blood tests
showed a basal CK level of 99 IU/L (N 30–200 IU/L).
Muscle magnetic resonance imaging (MRI) was normal.
The patient had been exposed to volatile anaes-
thetics on several occasions without any adverse reac-
tion. The family history was negative for signs of
myopathy and anaesthesia-related events.
Muscle biopsy performed three months after his last
episode of ER showed normal histological findings. In
vitro contracture testing for MH susceptibility accord-
ing to the protocol of the European Malignant
Hyperthermia Group (EMHG)2 was within normal
limits, ruling out MH susceptibility. Molecular genetic
analysis could not reveal any mutation in RYR1, nor in
the carnitine palmitoyl transferase 2 gene (CPT2).
Case 2. Male, 56 years of age. This patient presented
with myalgia after exercise described as a sensation of
severe tension or cramping pain, unilateral or bilateral.
The complaints were not related to the type of effort as
the pain could be elicited by only short exercise and was
not necessarily provoked by longer exercise. CK value
increased to 14,000 IU/L during one myalgia episode.
For years, he had been an amateur cyclist accustomed to
regular hour-long exercise. His complaints started at the
age of 40. There was no previous exposure to volatile
anaesthetics. Family history was negative for similar
types of complaints or anaesthesia-related events.
Clinical examination was normal. Basal CK value
was variably increased (269 to 1771 IU/L); lactate
was 1.2 mmol/L. Ischaemic forearm testing was
normal and muscle MRI could not detect any altera-
tions in muscle signal intensity. A muscle biopsy
showed increased variability in fibre size and an
increased number of internal nuclei. The in vitro con-
tracture test (IVCT) was indicative of MH susceptibil-
ity (5 mN contracture at 2 mM caffeine and 14 mN
contracture at 2 vol% halothane). CTP2 sequencing
was negative, but a heterozygous missense mutation
in exon 43 of RYR1 was identified (p.Asn2342Ser)
(this clinical case has previously been reported in a
paper focusing on the possible risk of administration
of volatile anaesthetics in patients with ER3).
Case 3. Female, 22 years of age. She was first investi-
gated at the age of 20 years, presenting with myalgia of
the lower limb muscles for two days and clinical myo-
globinuria. Neurological examination was unremark-
able, particularly regarding manual strength testing,
apart from tenderness of lower limb muscles. CK
level was 82,324 IU/L. She was admitted to the hospital
and intravenous hyperhydration was started. Recovery
was uneventful.
Retrospectively, she had experienced multiple epi-
sodes of muscle soreness and stiffness since the age of
ten years, when she manifested these symptoms for the
first time during a mountain walk. At the age of
14 years, she had had similar complaints during ballet
training. However, since then, these episodes had also
occurred in conjunction with viral upper respiratory
tract infections, stress (e.g. exams), skipping meals
and, as before, accustomed yet relatively prolonged
exercise of about one hour, even at normal or low
ambient temperatures.
Basal CK level was within normal limits. Plasma
acylcarnitine profiling in the acute phase of the rhab-
domyolysis showed low acetylcarnitine (C2). Muscle
MRI did not reveal any structural abnormalities.
Family history was negative with regard to muscle
symptoms and anaesthesia-related problems. Sanger
sequencing of CPT2 revealed the most recurrent
mutation, p.Ser113Leu, in homozygosity. In view of
this diagnosis, muscle biopsy and in vitro contracture
testing for MH susceptibility were not indicated.
Discussion
When dealing with ER, as in the cases presented, three
main questions have to be considered: first, is the
observed degree of rhabdomyolysis in relation to the
effort and circumstances or not; second, is there a risk
of recurrence; and third, is there a risk of other com-
plications, most notably anaesthesia-related MH?
A ‘physiological’ or ‘expected’ response of muscle to
exercise means either a minor to moderate degree of
muscle damage following strenuous exercise or a
more pronounced degree of rhabdomyolysis following
extreme or unaccustomed exercise. On the other hand,
muscle breakdown that occurs during or following
accustomed exercise in normal environmental condi-
tions with well-trained individuals has to be regarded
as an ‘unexpected’ or ‘pathological’ response.
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However, as terms such as ‘minor’, ‘moderate’, ‘stren-
uous’, ‘unaccustomed’ and ‘delayed’ are prone to sub-
jective interpretation, the distinction is hard to make.
Over the last few years, consensus has grown as to
what should be the definition of ER, a concept that
encompasses three key features:
1. A CK increase peaking at three to four days, fol-
lowed by normalization within several weeks.
2. The CK increase is preceded by strenuous exercise;
alternatively by accustomed exercise in abnormal
environmental circumstances.
3. The CK increase incurs a clinical correlate of myal-
gia, swelling and/or weakness of muscle (either gen-
eralized or in particular groups of muscle depending
on the type of exercise).1
It is well known that blood CK levels increase con-
siderably in the days following prolonged exercise and
remain elevated for several days. Of the 203 participants
subjected to 50 maximal eccentric contractions of the
elbow flexor muscles, 111 had CK values at four days
post-exercise of over 2,000 IU/L, and 51 exceeded
10,000 IU/L. At day 10 after the exercise, CK levels
were still 300% above baseline.4 As the upper limits of
normal levels already vary considerably between labora-
tories depending on the technique of measurement and
ethnicity,5 the matter is further complicated.
CK values felt to be indicative of an abnormal
degree of rhabdomyolysis have been variably reported
as: 5–50 times the upper limit, >1000 IU/L up to
>10,000 IU/L. However, one cannot rely solely on
CK levels to differentiate a physiological exertional
CK elevation from rhabdomyolysis based on an under-
lying cause. Indeed, other elements have to be taken
into consideration and, with this aim in mind, a screen-
ing tool with the acronym ‘RHABDO’ was published
in 2016 by Scalco et al.1 The following clues may point
to an underlying genetic disorder:
R: Recurrent episodes of ER
H: HyperCKaemia persists eight weeks after the event
A: Accustomed physical exercise
B: Blood CK> 50" upper limit of normal
(>10,000 IU/L in female Caucasian patients)
D: Drugs/medication/supplements and other exoge-
nous and endogenous factors cannot sufficiently
explain the rhabdomyolysis severity
O: Other family members affected/other exertional
symptoms (cramps or myalgia).
Applying this acronym tool to our patients resulted
in at least four risk factors warranting further investi-
gation being positive, whereas in fact a single one
would suffice. This is illustrated in Table 1.
The risk of ER recurrence is real if an underlying
genetic condition can be identified. Although many of
these are very rare, some inherited causes of rhabdo-
myolysis are more prevalent.
Even though the sickle cell trait has a very limited
effect on the physiological response to exercise, a
greater incidence of ER has been reported in such
patients over several decades.6 This has recently been
confirmed in a population-based, longitudinal study
conducted in US Army soldiers. A significantly
higher risk of ER was identified among black recruits
with the sickle cell trait than among those without the
trait.7 In the US, 7%–10% of the African population
has this trait. If the sickle cell trait is an underlying
cause, then muscle damage is triggered by effort and
has a variable time of onset: early, late or after the
event. The major diagnostic clue in such cases is being
of African descent.
Secondly, a number of inherited myopathies predis-
pose to ER. However, these are highly heterogeneous
and it is felt likely that polygenetic factors lead to the
huge variance in the degree of rhabdomyolysis in par-
ticular circumstances of vigorous exercise.8 Algorithms
for both a clinical diagnostic approach9 and the search
for a genetic defect10 have been developed, and are
very useful.
The inherited neuromuscular disorders associated
with episodes of adult-onset ER are classified into the
following categories: disorders of intramuscular calci-
um release and excitation–contraction coupling, disor-
ders of glycogen metabolism, disorders of fatty acid
metabolism, muscular dystrophies, mitochondrial dis-
orders and miscellaneous.10
The ‘most prevalent’ or ‘least rare’ myopathies are
RYR1-related disorders. RYR1 encodes the principal
sarcoplasmic reticulum calcium release channel and
plays a crucial role in excitation–contraction coupling.
RYR1 missense mutations have been found in 50%–
60% of families with proven MH.11 The possible link
between ER and MH susceptibility has been explored
in a number of studies over the last few years. A first
large series of 39 unrelated families with rhabdomyol-
ysis and/or exertional myalgia was published in 2013.12
Table 1. ‘RHABDO’ screening application.
Patient 1 Patient 2 Patient 3
R þ þ þ
H $ þ $
A þ þ þ
B þ þ þ
D þ þ þ
O $ þ þ
4/6 6/6 5/6
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Nine heterozygous mutations were reported in 14 fam-
ilies, five of which had previously been associated with
MH. Since then, it has been shown in different cohorts
of patients with ER that causative mutations or poten-
tially pathogenic variants in RYR1 and CACNA1S
account for a substantial proportion of patients
presenting with unexplained rhabdomyolysis and/or
exertional myalgia.13–15
It appears that this genetic predisposition in com-
bination with various stressors (e.g. inhalational
anaesthesia, viral infections, environmental heat,
strenuous exercise, severe stress and/or drugs) can
elicit acute rhabdomyolysis. Partly based on these
findings, the US Department of Defense defines MH
as a disqualifying condition to their fitness for duty
determinations.16
The second case illustrates the complex relationship
between ER, histopathology, MH susceptibility and
RYR1 analysis. This patient’s MH susceptibility
status was assessed and confirmed by in vitro contrac-
ture testing with halothane and caffeine. The test is
considered positive if a sustained contracture of at
least 2 mN is obtained at caffeine concentrations % 2
mM, and/or halothane concentrations of 2 vol% or
less. Normal individuals do not react at the threshold
concentrations of either agent. The test sensitivity is
99% and its specificity is 93.5%.17 Even though the
p.Asn2342Ser variant (previously reported in Italian
families18) is not classified as a true diagnostic mutation
in the EMHG genetic database (https://www.emhg.
org/diagnostic-mutations; accessed January 30 2019),
there is corroborative experimental evidence that this
mutation can be used for predictive genetic testing.
Indeed, the 4-chloro-m-cresol-induced proton release
rate of lymphoblastoid cells—as an indirect indicator
of activation of the RYR1 calcium channel—was
shown to be increased in the RYR1Asn2342Ser mutated
channels (and inhibited by dantrolene).18 In this
patient, the positive IVCT test suggested additional evi-
dence for pathogenicity. Therefore, we concluded that
he was clearly at risk for recurrent ER and MH, in all
likelihood on the basis of an RYR1 mutation with ‘gain
of function’ of the calcium release channel of the sar-
coplasmic reticulum. As MH is considered to be an
autosomal dominant disorder, his family members
also are at risk for this potentially life-threatening
anaesthesia complication. The histopathological
changes as such are non-specific but nevertheless con-
sistent with a RYR1 myopathy. Patient 1 is at risk for
recurrent ER, but not at risk for MH during anaesthe-
sia. An underlying condition could not be identified.
The familial implications remain unknown.
Regarding disorders of glycogen metabolism, the
most common disease in this group is glycogen storage
disease type V, McArdle’s disease. The trigger for rhab-
domyolysis is exercise with an early symptom onset,
which is within minutes. Therefore, these are not the
type of patients that will present with rhabdomyolysis
at the end of endurance exercise as described in these
cases. Baseline CK levels are high.
Other categories include:
1. Disorders of fatty acid metabolism. Carnitine
palmitoyl transferase deficiency due to autosomal-
recessive mutations in the CPT2 gene is the most
common disorder in this group. The severity of the
symptoms differs according to the degree of reduc-
tion in enzyme activity, with the more severe forms
expressed as fatal neonatal or infantile-onset var-
iants, and the less severe expressions as adult-onset
forms with exercise intolerance, myalgia and recur-
rent ER. In the latter group, prolonged (one hour)
exercise but also exposure to heat, infection, fasting
and stress can provoke a crisis. Baseline CK levels
are normal. CPT2 deficiency was found to be the
cause in the third patient. A second disorder of
fatty acid metabolism is a deficiency of very-long-
chain acyl-CoA dehydrogenase.
2. The muscular dystrophies are usually diagnosed
because of progressive weakness, but there is an
increased susceptibility for ER that may be the
presenting problem. Baseline CK level is high.
3. Mitochondrial DNA mutations associated with ER
are rare but have been reported in cases with muta-
tions in the cytochrome b and cytochrome c oxidase
genes. Early and excessive fatigue is a major physical
complaint, which is not the case for the other
groups, and which was not a complaint in the
patients investigated.
Defining a general diagnostic approach to ER in
adults is difficult in view of the multiple potential
genetic causes. The following algorithmic approach to
clinical decision-making can be used to differentiate the
more prevalent underlying myopathies (Figure 1).
Baseline investigations include identification of the
triggers for rhabdomyolysis as well as the relative
timing of onset, neurological examination, and serial
CK and myoglobinuria measurements.
Second-phase tests include non- or minimally inva-
sive tests such as fasting acyl-carnitine profiling, elec-
tromyography, ischaemic forearm testing and MRI.
Analysis of T1-weighted MRI images of pelvis, thigh
and leg muscles demonstrates significant differences in
the pattern of affected and spared muscles for a
4 Anaesthesia and Intensive Care 0(0)
number of myopathies, such as the muscular dystro-
phies and RYR1 myopathies.19,20 This may assist in
the prioritization of genetic testing of particular genes
such as RYR1.
If this is not the case, third-phase investigations such
as muscle biopsy may help in targeting genetic testing
and the most appropriate ‘myopathy/rhabdomyolysis
DNA sequencing panel’. The analytical sensitivity of
sequencing individual genes in patients with specific
clinical features, abnormal metabolites, and/or histo-
enzymatic deficiency is high; whereas this is much less
the case if no such presumptive diagnosis can be made.
In a significant proportion of patients presenting
with ER the precise underlying mechanism
remains unsolved.
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